8:20 am Chair’s Opening Remarks

8:30 am Talk Reserved for Abzena

Optimizing Linker Stability Within Circulation to Eliminate Off-Target Toxicities

9:00 am Understanding the Role of Linker Stability in Accurate Payload Release to Guide Targeted Delivery of Your ADC


• Delving into how varying levels of hydrophobicity in the linker affects the stability

• Analyzing how and where the linker degrades

• Understanding which linker chemistry creates the most stable ADC

9:30 am Examining How to Maintain Linker Stability in High DAR ADCs


• Understanding how a higher DAR affects linker stability

• Examining how you can counter an increase in hydrophilicity as a result of a higher DAR

• Demonstration how the increase the hydrophobicity of the linker ensures the payloads remain conjugated

10:00 am Selecting the Correct Level of Stability to Ensure a Maximized Therapeutic Index for Your ADC


• Discussing how site of conjugation and drug linker modifications can reduce some offtarget toxicities with anti-mitotic ADCs

• Exploring how increased drug-linker stability can shift the dose-limiting toxicity of antimitotic ADCs away from bone marrow and towards more problematic toxicities

• Learning how the instability of the vedotin drug linker could be a key driver to its clinical success

10:30 am Morning Refreshments & Speed Networking


This session is an opportunity to connect with peers and hold in-depth conversations with some of the brightest minds in the ADC chemistry field to establish meaningful and lasting relationships.

Outlining Design Parameters to Increase Stability & Maximize Targeted Delivery

11:30 am Designing the Linker Efficiently to Ensure It Activates in the Correct Space

  • Donglu Zhang Senior Fellow - Drug Metabolism & Pharmacokinetics, Genentech


• Understanding how linker design affects activation

• Modulating the linker chemistry to make activation in the correct space possible

• Designing the linker to navigate tumor properties

12:00 pm A Reliable & Flexible Technology for the Rapid Conjugation of Antibodies & Other Biologics


• Discussing how Singzyme’s technology accelerates the development of cancer immunotherapy, allowing faster production of antibody-drug conjugates with minimal footprint on the final product and the possibility to attach two payloads with a defined DAR

• Examining how this technology also allows imaging for disease diagnosis: production of radiopharmaceuticals for PET scan imaging (Nanobodies or mAbs) with minimal radioactive waste thanks to the highest conjugation efficiency on the market

12:30 pm Networking Lunch

1:00 pm Tumour-Selective Linker Chemistries

  • Robert Lutz Chief Scientific Officer, Iksuda Therapeutics


Talk Details TBC

1:30 pm Overcoming Chemical Diversity to Create a Focused Design Criteria for Your Linker


• Navigating the large chemical space of ADC linker

• Using the vast chemical space to design the most clinically relevant linker

• Focusing on what design criteria are the most important for your linker

Examining Novel Linkers to Expand Your Linker Chemistry Toolkit

2:00 pm Looking Beyond Cathepsins: Understanding & Optimizing Legumain- Cleavable ADC Linkers


• Overviewing the development of peptide libraries screened to identify new ADC linkers

• Demonstrating mechanism of legumain-cleavable linkers

• Learning functional and biophysical differentiation of legumain-cleavable linkers from cathepsin-cleavable linkers

2:30 pm Linker Matters: Highly Stable and Efficacious ADCs Made with Native Antibodies and Peptide Linkers


• Distinct biophysical properties and greatly enhanced stability

• Improved pharmacokinetics, efficacy and safety

• Resulting in ADCs show improved therapeutic indices vs FDA-approved ADCs

3:00 pm Afternoon Networking Break & Scientific Poster Session


  • This is an informal session to help you connect with your peers in a relaxed atmosphere and continue forging new and beneficial relationships. You will have the opportunity to present your work, and review presentations displaying novel approaches and findings.

4:00 pm Panel Discussion:Comparing Existing & Novel Linkers to Identify the Most Relevant Linkers to Take Into Your Early Drug Development


• Understanding if novel linkers are better than clinically active candidates

• Analyzing the difference in chemistry between novel linkers and existing ones

• Exploring how the development of novel linkers affects overall ADC

4:45 pm Chair’s Closing Remarks

5:00 pm Drinks Reception

6:00 pm End of Scientific Program Day One